UNLABELLED: This study assessed the effect of estradiol, raloxifene and genistein on the preservation of bone 3D-microarchitecture and volumetric bone mineral density (vBMD) in the ovariectomized mouse model. Our results indicated that raloxifene was more effective in preserving bone ovariectomized-induced changes, the advantage being concentrated in both bone microarchitecture and vBMD. INTRODUCTION: This study assessed the effect of different estrogen receptor (ER) agonists on the preservation of bone 3D-microarchitecture and volumetric bone mineral density (vBMD) in the ovariectomized (OVX) mouse model. METHODS: Twelve-week-old female C57BL/6 mice were randomly assigned to one of five groups: (1) SHAM-operated + vehicle; (2) OVX + vehicle; (3) OVX + 17beta-estradiol (5 microg/kg); (4) OVX + raloxifene (1 mg/kg); (5) OVX + genistein (25 mg/kg), during 4-weeks. Bone microarchitecture and trabecular, cortical and total vBMD of distal femur were imaged by ex vivo microcomputed tomography (micro-CT). RESULTS: Ovariectomy produced a global deterioration involving both trabecular and cortical 3D-microarchitecture and vBMD. Raloxifene maintained both microarchitecture and vBMD, whereas estradiol prevented deterioration of some microstructural parameters, such as trabecular thickness (Tb.Th), trabecular bone pattern factor (Tb.Pf), and cortical periosteal perimeter (Ct.Pe.Pm), but did not completely block the loss in vBMD. Mice treated with genistein exhibited the less favourable profile in both vBMD and microstructural parameters preserving only cross-sectional bone area (B.Ar) and Ct.Pe.Pm in cortical bone. CONCLUSION: Our data indicate that, at the selected doses, raloxifene was more effective in preserving bone OVX-induced changes than either estradiol or genistein, the advantage being concentrated in both bone microarchitecture and vBMD.
UNLABELLED: This study assessed the effect of estradiol, raloxifene and genistein on the preservation of bone 3D-microarchitecture and volumetric bone mineral density (vBMD) in the ovariectomized mouse model. Our results indicated that raloxifene was more effective in preserving bone ovariectomized-induced changes, the advantage being concentrated in both bone microarchitecture and vBMD. INTRODUCTION: This study assessed the effect of different estrogen receptor (ER) agonists on the preservation of bone 3D-microarchitecture and volumetric bone mineral density (vBMD) in the ovariectomized (OVX) mouse model. METHODS: Twelve-week-old female C57BL/6 mice were randomly assigned to one of five groups: (1) SHAM-operated + vehicle; (2) OVX + vehicle; (3) OVX + 17beta-estradiol (5 microg/kg); (4) OVX + raloxifene (1 mg/kg); (5) OVX + genistein (25 mg/kg), during 4-weeks. Bone microarchitecture and trabecular, cortical and total vBMD of distal femur were imaged by ex vivo microcomputed tomography (micro-CT). RESULTS: Ovariectomy produced a global deterioration involving both trabecular and cortical 3D-microarchitecture and vBMD. Raloxifene maintained both microarchitecture and vBMD, whereas estradiol prevented deterioration of some microstructural parameters, such as trabecular thickness (Tb.Th), trabecular bone pattern factor (Tb.Pf), and cortical periosteal perimeter (Ct.Pe.Pm), but did not completely block the loss in vBMD. Mice treated with genistein exhibited the less favourable profile in both vBMD and microstructural parameters preserving only cross-sectional bone area (B.Ar) and Ct.Pe.Pm in cortical bone. CONCLUSION: Our data indicate that, at the selected doses, raloxifene was more effective in preserving bone OVX-induced changes than either estradiol or genistein, the advantage being concentrated in both bone microarchitecture and vBMD.
Authors: Miguel Angel García-Pérez; Rosa Noguera; Raquel del Val; Inmaculada Noguera; Carlos Hermenegildo; Antonio Cano Journal: Fertil Steril Date: 2006-09-11 Impact factor: 7.329
Authors: L M McNamara; A G H Ederveen; C G Lyons; C Price; M B Schaffler; H Weinans; P J Prendergast Journal: Bone Date: 2006-04-27 Impact factor: 4.398
Authors: M A García-Pérez; R Del Val; I Noguera; C Hermenegildo; B Pineda; A Martinez-Romero; A Cano Journal: Int J Immunopathol Pharmacol Date: 2006 Oct-Dec Impact factor: 3.219
Authors: G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson Journal: Endocrinology Date: 1998-10 Impact factor: 4.736
Authors: Yu Shao; Selene Hernandez-Buquer; Paul Childress; Keith R Stayrook; Marta B Alvarez; Hannah Davis; Lilian I Plotkin; Yongzheng He; Keith W Condon; David B Burr; Stuart J Warden; Alexander G Robling; Feng-Chun Yang; Ronald C Wek; Matthew R Allen; Joseph P Bidwell Journal: Endocrinology Date: 2017-09-01 Impact factor: 4.736
Authors: LeeCole L Legette; Wang-Hee Lee; Berdine R Martin; Jon A Story; Ali Arabshahi; Stephen Barnes; Connie M Weaver Journal: Menopause Date: 2011-08 Impact factor: 2.953
Authors: Nadia Mohd Effendy; Shahrum Abdullah; Mohd Faridz Mod Yunoh; Ahmad Nazrun Shuid Journal: BMC Complement Altern Med Date: 2015-03-12 Impact factor: 3.659
Authors: Kamini Srivastava; Kainat Khan; Abdul M Tyagi; Mohd P Khan; Dinesh K Yadav; Ritu Trivedi; Rakesh Maurya; Divya Singh; Naibedya Chattopadhyay Journal: Evid Based Complement Alternat Med Date: 2013-04-27 Impact factor: 2.629